ProteoNic and NecstGen Establish Partnership to Improve Viral Vector Manufacturing Efficiency for Gene Therapies
ProteoNic and NecstGen announce a partnership for the development of improved viral vector manufacturing for gene therapy applications. Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
Source: b3cnewswire.com